Mesoblast completes Phase 3 low back pain trial treatment as pivotal readout approaches
Mesoblast has completed treatment of 350 patients in its pivotal Phase 3 trial for chronic low back pain, with results expected in mid-2027.
Currently unlisted.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Announcements
Filter Results
| AUG Appointment of new director | |||
| 29/03/18 | |||
| AUG Settlement of retail title at Finance Centre | |||
| 29/03/18 | PRICE SENSITIVE | ||
| AUG Settlement of acquisition of NPT management rights | |||
| 27/03/18 | |||
| AUG AUGUSTA’S LATEST CAPITAL RAISING CLOSES OVERSUBSCRIBED | |||
| 26/03/18 | PRICE SENSITIVE | ||
| AUG NPT ADDS 10% TO AUGUSTA’S ASSETS UNDER MANAGEMENT | |||
| 19/03/18 | PRICE SENSITIVE | ||
| AUG Industrial Fund - Confirmation of additional property | |||
| 08/03/18 | PRICE SENSITIVE | ||
| AUG Industrial Fund - Update | |||
| 01/03/18 | PRICE SENSITIVE | ||
| AUG Confirmation of date for NPT shareholder meeting | |||
| 01/03/18 | |||
